



February 11, 2022

Dear Lafora Disease Community,

In September of last year, we shared with you our plans to initiate the first clinical study in patients with Lafora disease in 2022 at the earliest. Regrettably, due to organizational constraints, in particular human resources needed to start a new clinical program, we write today to inform you that the initiation of a clinical study this year is unlikely. We fully appreciate that for a condition such as Lafora disease, delay is disappointing. We continue to explore potential alternative options.

Everyone at Ionis recognizes that this news is disappointing for families affected by Lafora disease. We are committed to continue working closely with the community and explore potential alternative options.

Sincerely,
The Ionis Team

CC: Kristina Bowyer, VP of Patient Centric Drug Development
patients@ionisph.com